Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2 -amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.
Authors
- Yixing Jiang (ORCID: https://orcid.org/0000-0002-0013-1807)
- Phillip M. Garfin
- Madappa N. Kundranda (ORCID: https://orcid.org/0000-0002-9237-2666)
- Laëtitia Dahan (ORCID: https://orcid.org/0000-0001-5267-6190)
- Ari David Baron (ORCID: https://orcid.org/0000-0003-1247-3094)
- Marine Jary (ORCID: https://orcid.org/0000-0001-7502-7708)
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Mohamedtaki Abdulaziz Tejani
- Roberto Pazo-Cid (ORCID: https://orcid.org/0000-0002-8026-7391)
- Muhammad Shaalan Beg (ORCID: https://orcid.org/0000-0002-3754-6627)
- Elisabetta Fenocchio (ORCID: https://orcid.org/0000-0001-6679-0955)
- J. Adeva Alfonso
- Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
- Myung Ah Lee (ORCID: https://orcid.org/0000-0002-1204-0574)
- Aaron J. Scott (ORCID: https://orcid.org/0000-0002-0301-3072)
- Lequn Bao
- Roopinder Gillmore (ORCID: https://orcid.org/0000-0001-8620-3885)
- Daneng Li (ORCID: https://orcid.org/0000-0001-5330-7522)
- David Tougeron (ORCID: https://orcid.org/0000-0002-8065-9635)
- Andrés Jesús Muñoz Martín (ORCID: https://orcid.org/0000-0001-6977-8249)
- Jieer Ying (ORCID: https://orcid.org/0000-0001-9452-1242)
- Laura Layos (ORCID: https://orcid.org/0000-0002-0537-6061)
- Shubham Pant (ORCID: https://orcid.org/0000-0001-9055-8494)
- Benjamin Tan (ORCID: https://orcid.org/0000-0003-1838-1182)
- Omkar Marathe
- Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
- Qiang Yan (ORCID: https://orcid.org/0000-0001-6102-7053)
- Massimo Aglietta (ORCID: https://orcid.org/0000-0002-2255-7972)
- Antonio Cubillo Gracián
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Jung Hun Kang (ORCID: https://orcid.org/0000-0001-5013-2683)
- Emerson Y. Chen (ORCID: https://orcid.org/0000-0003-3035-4478)
- Harpreet Wasan (ORCID: https://orcid.org/0000-0002-6268-2030)
- Lorenza Rimassa (ORCID: https://orcid.org/0000-0001-9957-3615)
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Sebastián Mondaca (ORCID: https://orcid.org/0000-0002-1130-0370)
- Jean‐Philippe Metges (ORCID: https://orcid.org/0000-0003-0728-0861)
- Ghassan K. Abou‐Alfa (ORCID: https://orcid.org/0000-0002-1522-8054)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- John A. Bridgewater (ORCID: https://orcid.org/0000-0001-9186-1604)
- Michel Ducreux (ORCID: https://orcid.org/0000-0001-8649-7449)
- Olumide Gbolohon
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-4728-0180)
- Jin Won Kim (ORCID: https://orcid.org/0000-0002-8370-2539)
- Jia Fan (ORCID: https://orcid.org/0000-0001-5158-629X)
- Ying Cheng (ORCID: https://orcid.org/0000-0002-8940-8445)
- Yi Zhao (ORCID: https://orcid.org/0000-0002-6668-9889)
- Xiaotian Wu (ORCID: https://orcid.org/0000-0002-0288-9099)
- Rosa Alonso
- Yuanyuan Bao
- Hye Jin Choi
- Saeed Sadeghi (ORCID: https://orcid.org/0000-0002-4062-0170)
- Paula Ribera Fernandez (ORCID: https://orcid.org/0009-0000-9933-6126)
- Jonathon Gable
- Joon Oh Park
- Paula Carrasco Aguirre
- Heung-Moon Chang
- Feng Xie (ORCID: https://orcid.org/0000-0003-3883-6930)
- Gentry George King
- Milind Javle
- James J. Harding
- Tingbo Liang (ORCID: https://orcid.org/0000-0003-0143-3353)
- Xiaoyu Yin (ORCID: https://orcid.org/0000-0002-5578-3407)
Institutions
- Ulsan College (KR)
- Hebron University (PS)
- Verizon (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Sun Yat-sen University (CN)
- Oregon Health & Science University (US)
- Yonsei University (KR)
- Cornell University (US)
- Fudan University (CN)
- Université Paris-Saclay (FR)
- Asan Medical Center (KR)
- Hammersmith Hospital (GB)
- Institut Gustave Roussy (FR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- London Cancer (GB)
- Zhejiang Cancer Hospital (CN)
- Jazz Pharmaceuticals (United States) (US)
- Beijing Enterprises (China) (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Cancer Institute of Florida (US)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Chinese People's Liberation Army (CN)
- Hubei Cancer Hospital (CN)
- University College London (GB)
- Imperial College London (GB)
- Catholic University of Korea (KR)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1001/jamaoncol.2025.4736
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Celgene
- Exelixis
- Jazz Pharmaceuticals
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- G1 Therapeutics
- Seagen
- Servier
- Sirtex Medical
- Genentech
- Foundation Medicine
- Daiichi Sankyo Europe